-
FSCDR Presents Positive Results from Case Study of Voxelotor (GBT440) in Sickle Cell Disease Patient
Additional Photographs Added as of April 5, 2023. Some text has been updated to reflect present-day. HOLLYWOOD, Fla., — Oct.Read More…
Read More -
FSCDR’s Experience with Voxelotor (GBT440) Treatment in Patients with Severe Sickle Cell Disease
ATLANTA — Lanetta Bronté, M.D., M.P.H., M.S.P.H., founder and chief health officer of the Foundation for Sickle Cell Disease ResearchRead More…
Read More
